* Alteon Inc., of Ramsey, N.J., said it discovered a novel class oforally available compounds that lowers blood glucose and free fattyacid levels in animal models of Type II diabetes. The class, called theGlucose Lowering Agents series, is distinct from the glitazonecompounds, with similar therapeutic effects but fewer toxicities.
* Aronex Pharmaceuticals Inc., of The Woodlands, Texas, approveda 1-for-2 reverse stock split, which will become effective July 1,1996.
* Boehringer Ingelheim Pharmaceuticals Inc., of Ridegfield, Conn.,received an FDA advisory committee recommendation foraccelerated approval of Viramune (nevirapine) in combination withnucleoside analogues for HIV. While nucleoside analogues preventthe growth of the DNA chain, non-nucleoside drugs such asViramune directly inactivate the enzyme.
* Cell Genesys Inc., of Foster City, Calif., earned a $2 millionmilestone payment from Hoechst Marion Roussel, of Frankfurt,Germany, for initial patient enrollment in a Phase II trial testing itsAIDS gene therapy approach. Patients will receive infusions of theirown T cells that have been genetically modified ex vivo with HIV-specific receptors. The receptors enable the T cells to recognize anddestroy HIV-infected cells.
* Enzon Inc., of Piscataway, N.J., said it realized a net profit of $1million after exercising 150,00 warrants to purchase shares ofNeoprobe Corp., of Dublin, Ohio. The warrants were received whenEnzon licensed its single-chain antigen-binding technology toNeoprobe.
* Genentech Inc., of South San Francisco, discontinued pursuingActimmune (interferon gamma-1b) for renal cell carcinoma. Analysisof Phase III data showed no significant benefit in that indication.
* Genta Inc., of San Diego, reported interim Phase I/IIa data showingno dose-limiting or dose-related toxicities from its Anticode(antisense) treatment in non-Hodgkin's lymphoma patients. In nearlyhalf the patients biological activity was noted, with minor tumorresponse seen in some patients.
* Genzyme Corp., of Cambridge, Mass., declared a 2-for-1 stocksplit. It will be made in the form of a dividend distributed on July 25,1996, to shareholders of record on July 11, 1996.
* Gliatech Inc., of Cleveland, withdrew a proposed offering of 1.75million shares. The company said a stock drop of late undervaluesGliatech.
* Seragen Inc., of Hopkinton, Mass., raised $4 million through thesale of 4,000 shares of Series A convertible preferred stock toinstitutional investors outside the U.S. The stock is convertiblebeginning in July 1996 at the lesser of the closing bid price on May28, 1996, or 73 percent of the average closing bid prices for aspecified period of time before conversion. Terms call for dividendspayable in common shares.
* SyStemix Inc., of Palo Alto, Calif., said five shareholders filedlawsuits to stop the proposed acquisition by Sandoz Ltd., of Basel,Switzerland. Sandoz offered $17 per share for the 27 percent ofSyStemix it doesn't already own.
* BioNumerik Pharmaceuticals, of San Antonio, entered into aproduct development agreement with Grelan Pharmaceutical Co., ofTokyo, for development of BioNumerik's cisplatin protecting agent,BNP7787, in Japan. BioNumerik will receive an undisclosed initialpayment and an equity investment.
* Carrington Laboratories Inc., of Irving, Texas, said it plans toinitiate a second Phase III trial of Aliminase (CARN 1000) inpatients with ulcerative colitis. The decision was based on an interimanalysis of an ongoing double-blind, placebo-controlled study in 288patients.
* Innovir Laboratories Inc., of New York, entered a collaborationwith The Scripps Research Institute, of La Jolla, Calif., to evaluate inanimal models a new drug candidate for chronic hepatitis B. The leaddrug comes from a class of compounds developed using Innovir'ssite-specific External Guide Sequence technology, and will bedelivered by the company's new system to facilitate entry into livercells.
* Interferon Sciences Inc., of New Brunswick, N.J., said its low-doseoral alpha interferon, Alferon LDO, and two other low-dose alphainterferon products will be compared to placebo in a study testing theeffectiveness in reducing the symptoms of AIDS. Enrollment hasbegun in the 560-patient study sponsored by the National Institute ofAllergy and Infectious Diseases.
* Rhone-Poulenc Rorer Inc., of Collegeville, Pa., said Rilutek wascleared for marketing as a treatment for amyotrophic lateral sclerosisin the European Union's 15 member countries.
* Scios Inc., of Mountain View, Calif., said the Opposition Divisionof the European Patent Office (EPO) ruled in its favor in anopposition related to Fiblast trafermin, the company's recombinantbasic fibroblast growth factor. The ruling confirms an earlier EPOdecision to issue a patent to Scios and rejects the opposition filed byChiron Corp., of Emeryville, Calif., and Pharmacia S.p.A., ofSweden.
* Somatogen Inc., of Boulder, Colo., began a Phase I trial of itsrecombinant hemoglobin, rHb1.1, as an agent for stimulating redblood cell formation. The study will evaluate safety andhematopoietic activity in about 50 patients with anemia resultingfrom end stage renal disease.
* The Liposome Co., of Princeton, N.J., received marketing approvalfor Abelcet (amphotericin B lipid complex injection) in Sweden totreat severe, invasive fungal infections in refractory and otherpatients.
(c) 1997 American Health Consultants. All rights reserved.